ChemoCentryx Inc (CCXI):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:ChemoCentryx Inc (CCXI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C7994
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:35
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ChemoCentryx Inc (ChemoCentryx) is a biopharmaceutical company that discovers, develops and commercializes orally-administered therapeutics for the treatment of cancer, autoimmune diseases, and inflammatory disorders. The company’s lead drug candidate include Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis; CCX872, an orally administered inhibitor for pancreatic cancer; and CCX140, an orally-administered inhibitor of the chemokine receptor known for patients with diabetic nephropathy, among others. It also carries out preclinical research for evaluating the effect of combination therapy with chemokine receptor and check point inhibitors. ChemoCentryx is headquartered in Mountain View, California, the US.

ChemoCentryx Inc (CCXI) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ChemoCentryx Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
ChemoCentryx to Raise USD50 Million in Financing 10
Licensing Agreements 11
Vifor Pharma Enters into Licensing Agreement with ChemoCentryx 11
Vifor Pharma Expands Licensing Agreement with ChemoCentryx for CCX168 12
Equity Offering 13
ChemoCentryx Withdraws Public Offering of Shares for USD75 Million 13
ChemoCentryx Completes Public Offering Of Common Stock For US$69 Million 15
ChemoCentryx Raises USD7 million in Private Placement of Shares 16
ChemoCentryx Completes IPO Of Common Stock For US$45 Million 17
ChemoCentryx Completes Private Placement Of Shares For US$5 Million 19
Acquisition 20
Vifor Pharma to Acquire 14.6% Stake in Chemocentryx from GlaxoSmithKline 20
ChemoCentryx Inc – Key Competitors 22
ChemoCentryx Inc – Key Employees 23
ChemoCentryx Inc – Locations And Subsidiaries 24
Head Office 24
Other Locations & Subsidiaries 24
Recent Developments 25
Financial Announcements 25
Aug 09, 2018: Chemocentryx reports second quarter 2018 financial results and recent highlights 25
May 09, 2018: ChemoCentryx Reports First Quarter 2018 Financial Results and Recent Highlights 27
Mar 09, 2018: ChemoCentryx Reports Fourth Quarter And Full Year 2017 Financial Results And Recent Highlights 28
Nov 07, 2017: ChemoCentryx Reports Third Quarter 2017 Financial Results and Recent Highlights 30
Aug 08, 2017: ChemoCentryx Reports Second Quarter 2017 Financial Results and Recent Highlights 31
May 10, 2017: ChemoCentryx Reports First Quarter 2017 Financial Results 32
Mar 14, 2017: ChemoCentryx Reports Fourth Quarter and Full Year 2016 Financial Results 33
Corporate Communications 34
Jan 08, 2018: ChemoCentryx Strengthens Senior Executive Team with the Appointment of William Fairey as Executive Vice President and Chief Operating Officer 34
Appendix 35
Methodology 35
About GlobalData 35
Contact Us 35
Disclaimer 35

List of Tables
ChemoCentryx Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2
ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ChemoCentryx Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ChemoCentryx Inc, Deals By Therapy Area, 2012 to YTD 2018 8
ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
ChemoCentryx to Raise USD50 Million in Financing 10
Vifor Pharma Enters into Licensing Agreement with ChemoCentryx 11
Vifor Pharma Expands Licensing Agreement with ChemoCentryx for CCX168 12
ChemoCentryx Withdraws Public Offering of Shares for USD75 Million 13
ChemoCentryx Completes Public Offering Of Common Stock For US$69 Million 15
ChemoCentryx Raises USD7 million in Private Placement of Shares 16
ChemoCentryx Completes IPO Of Common Stock For US$45 Million 17
ChemoCentryx Completes Private Placement Of Shares For US$5 Million 19
Vifor Pharma to Acquire 14.6% Stake in Chemocentryx from GlaxoSmithKline 20
ChemoCentryx Inc, Key Competitors 22
ChemoCentryx Inc, Key Employees 23
ChemoCentryx Inc, Subsidiaries 24

List of Figures
ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ChemoCentryx Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[ChemoCentryx Inc (CCXI):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Jakks Pacific, Inc.
    Jakks Pacific, Inc. - Strategy, SWOT and Corporate Finance Report Summary Jakks Pacific, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Tutunski Kombinat AD Prilep:企業の戦略・SWOT・財務分析
    Tutunski Kombinat AD Prilep - Strategy, SWOT and Corporate Finance Report Summary Tutunski Kombinat AD Prilep - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Nisshinbo Holdings, Inc.:企業の戦略・SWOT・財務情報
    Nisshinbo Holdings, Inc. - Strategy, SWOT and Corporate Finance Report Summary Nisshinbo Holdings, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Mylan N.V.:企業のM&A・事業提携・投資動向
    Mylan N.V. - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Mylan N.V. Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capi …
  • Visioneering Technologies Inc (VTI):企業の製品パイプライン分析2018
    Summary Visioneering Technologies Inc (VTI) is a medical device company that offers ophthalmic solutions. The company develops a portfolio of technologies to address eye care issues such as presbyopia, myopia and astigmatism. Its technology includes myopia correction technology, silicone hydrogel ma …
  • MSM Malaysia Holdings Berhad (MSM):企業の財務・戦略的SWOT分析
    MSM Malaysia Holdings Berhad (MSM) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Jellagen Pty Ltd-医療機器分野:企業M&A・提携分析
    Summary Jellagen Pty Ltd (Jellagen) is a provider of medical grade collagen products. The company’s products offer medical grade collagen supplied in the form of hydragel used in wound dressing, soft tissue regeneration, tissue engineering and haemostats. Its product pipeline offer scaffolds which c …
  • Agro Tech Foods Limited:企業の戦略・SWOT・財務情報
    Agro Tech Foods Limited - Strategy, SWOT and Corporate Finance Report Summary Agro Tech Foods Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service off …
  • Grupa Azoty SA (ATT):企業の財務・戦略的SWOT分析
    Grupa Azoty SA (ATT) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Lightbridge Corporation (LTBR):電力:M&Aディール及び事業提携情報
    Summary Lightbridge Corporation (Lightbridge) is a nuclear fuel technology company, which develops thorium based nuclear fuel technologies for nuclear reactor systems, that increases the power output of commercial reactors; generates nuclear energy and the amount of nuclear waste on a per-megawatt-h …
  • Citizens Electric Corporation:企業の発電所・SWOT分析2018
    Citizens Electric Corporation - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on key …
  • Old National Bancorp:企業のM&A・事業提携・投資動向
    Old National Bancorp - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Old National Bancorp Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A …
  • Johnson & Johnson (JNJ):医療機器:M&Aディール及び事業提携情報
    Summary Johnson & Johnson (J&J) researches and develops, and manufactures and sells a range of pharmaceutical products, medical devices and consumer products. The company provides pharmaceuticals for immune diseases, cancer, neurological disorders, infectious, cardiovascular and metabolic diseases; …
  • Depomed, Inc.:企業の戦略・SWOT・財務情報
    Depomed, Inc. - Strategy, SWOT and Corporate Finance Report Summary Depomed, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • CytoSorbents Corp (CTSO):企業の財務・戦略的SWOT分析
    Summary CytoSorbents Corp (CytoSorbents), formerly MedaSorb Technologies Corp, is a critical care immunotherapy company that develops blood purification products. Its flagship product, CytoSorb is an extracorporeal cytokine adsorber that is designed to control extreme systemic inflammation in seriou …
  • Chronix Biomedical Inc:医療機器:M&Aディール及び事業提携情報
    Summary Chronix Biomedical Inc (Chronix Biomedical) is a molecular diagnostic company that develops blood tests for monitoring minimal residual disease in cancer patients. The company offers tests such as second opinion tests and delta dot tests. Its second opinion tests include supplementary blood …
  • Luxfer Holdings PLC (LXFR):企業の財務・戦略的SWOT分析
    Luxfer Holdings PLC (LXFR) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Sysmex Corp (6869):企業の製品パイプライン分析2018
    Summary Sysmex Corp (Sysmex) is a supplier of medical devices. It researches, develops, manufactures and sells instruments, reagents, and software applications that facilitate health checkups, treatment and disease management. The company offers diagnostic instruments, reagents and laboratory inform …
  • Silex Systems Ltd (SLX):企業の財務・戦略的SWOT分析
    Summary Silex Systems Ltd (Silex) is a research and development company that offers technology solutions. The company develops, and commercializes technologies in solar energy, nuclear energy, and advanced materials and instrumentation. It develops utility-scale concentrating photovoltaic technology …
  • Blackline Safety Corp. (BLN):企業の財務・戦略的SWOT分析
    Blackline Safety Corp. (BLN) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆